Dongguan, China

Zhixin Cheng

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Sunshine Lake Pharma Co., Ltd.. Active years: 2018.


% Patents Active = 100.0


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zhixin Cheng: Innovator in Pharmaceutical Chemistry

Introduction

Zhixin Cheng is a prominent inventor based in Dongguan, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on substituted urea derivatives. His research focuses on developing compounds that can be utilized in the treatment of proliferative diseases.

Latest Patents

Zhixin Cheng holds a patent for "Substituted urea derivatives and pharmaceutical uses thereof." This patent presents novel substituted urea derivatives and their pharmaceutical compositions. The compounds are designed for preventing, managing, treating, or lessening a proliferative disease, as well as modulating the activity of protein kinase. He has 1 patent to his name.

Career Highlights

Cheng is currently employed at Sunshine Lake Pharma Co., Ltd., where he continues to advance his research and development efforts. His work has been instrumental in creating new therapeutic options for patients suffering from various diseases.

Collaborations

Zhixin Cheng collaborates with talented colleagues, including Changchung Cheng and Yingjun Zhang. Their combined expertise enhances the innovative capacity of their projects and contributes to the success of their research initiatives.

Conclusion

Zhixin Cheng is a dedicated inventor whose work in pharmaceutical chemistry is paving the way for new treatments. His contributions to the field are noteworthy and reflect his commitment to improving healthcare through innovation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…